Synthesis of monofunctional platinum(iv) carboxylate precursors for use in Pt(iv)–peptide bioconjugates
- 18 October 2018
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 47 (43) , 15465-15476
Abstract
Herein we present platinum(IV) bioconjugates with polyarginine peptides as prospective prodrug delivery systems. Asymmetrical platinum(IV) complexes 3 were obtained via oxidation of parent platinum(II) complexes 2 with N-bromosuccinimide (NBS) in the presence of succinic anhydride. The combination of these two oxidation reagents furnishes the platinum(IV) environment with two different axial ligands, one of which bears a free carboxylic acid. All platinum(II) and (IV) compounds were characterized by FT-IR, ESI-MS, HPLC, 1H-, 13C- and 195Pt-NMR. Standard solid-phase peptide chemistry was used for the synthesis of polyarginine (R9) peptides. Coupling of the platinum complexes with peptides N-terminally afforded peptide monoconjugates, which were purified by semi-preparative HPLC and characterized by analytical HPLC and ESI-MS. Platinum(IV)–peptide bioconjugates as well as platinum(II) and platinum(IV) complexes were tested as cytotoxic agents against two different human cancer cell lines (MCF-7, HepG2) and normal human fibroblasts cell lines (GM5657T). Preliminary in vitro data showed that all platinum(IV) complexes exhibit lower activity than their platinum(II) precursors towards most cell lines. Interestingly, in the case of HepG2 cells, the Pt(IV)-(R)9-G-A-L bioconjugate (4a) showed even higher activity compared to the non-targeting platinum(IV) parent compound.Keywords
This publication has 46 references indexed in Scilit:
- Redox activation of metal-based prodrugs as a strategy for drug deliveryAdvanced Drug Delivery Reviews, 2012
- The preparation and characterization of trans-platinum( iv ) complexes with unusually high cytotoxicityDalton Transactions, 2010
- The status of platinum anticancer drugs in the clinic and in clinical trialsDalton Transactions, 2010
- Current applications and future potential for bioinorganic chemistry in the development of anticancer drugsDrug Discovery Today, 2009
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC TrialJournal of Clinical Oncology, 2009
- The mechanism of action of platinum anticancer agents—what do we really know about it?Dalton Transactions, 2009
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Clinical Pharmacokinetics and Administration of Established Platinum DrugsDrugs, 2000
- Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum ElectrodeNature, 1965
- Solid Phase Peptide Synthesis. I. The Synthesis of a TetrapeptideJournal of the American Chemical Society, 1963